CD4 and melanoma: We show that broader clonal T-cell responses especially in CD4+ T cells before immunotherapy, as revealed by more diversified T-cell clones particularly of CD4+ T cells, may favor longer survival of melanoma patients with blockade of CTLA4 and that similar conditions may apply to long survivals under PD-1 inhibition as well.